» Articles » PMID: 34619430

Symptomatic Post-vaccination SARS-CoV-2 Infections in Healthcare Workers- A Multicenter Cohort Study

Overview
Specialty Endocrinology
Date 2021 Oct 7
PMID 34619430
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Aims: During the COVID-19 vaccination program in India, the healthcare workers were given the first priority. There are concerns regarding the occurrence of breakthrough infections after vaccination. We aimed to investigate the effictiveness of COVID-19 vaccines in preventing and reducing the severity of post-vaccination infections.

Methods: This retrospective test-negative case-control study examined 28342 vaccinated healthcare workers for symptomatic SARS-CoV-2 infections between January 16 to June 15, 2021. They worked at 43 Apollo Group hospitals in 24 Indian cities. These cohorts received either ChAdOx nCOV-19 (Recombinant) or the whole virion inactivated Vero cell vaccines. Various demographic, vaccination related and clinical parameters were evaluated.

Results: Symptomatic symptomatic post-vaccination infections occurred in a small number of vaccinated cohorts (5.07%, p < 0.001), and these were predominantly mild and did not result in hospitalization (p < 0.0001), or death. Both vaccines provided similar protection, with symptomatic infections in 5.11% and 4.58%, following ChAdOx nCOV-19 (Recombinant) and the whole virion inactivated Vero cell vaccines, respectively (p < 0.001). Nursing and Clinical staff and cohorts >50 years contracted more infections (p < 0.001). Two-dose vaccination has significantly lower odds of developing symptomatic infection (0.83, 95%CI - 0.72 to 0.97). Maximum infections occurred during the peak of the second COVID-19 wave from mid-April to May 2021 (p < 0.001). No significant difference existed in the infection between sex, vaccine type, and the number of vaccine doses received (p ≥ 0.05).

Conclusion: Symptomatic infections occurred in a small percentage of healthcare workers after COVID vaccination. Vaccination protected them from not only infection but also severe disease.

Citing Articles

COVID-19 vaccines are effective at preventing symptomatic and severe infection among healthcare workers: A clinical review.

Galgut O, Ashford F, Deeks A, Ghataure A, Islam M, Sambhi T Vaccine X. 2024; 20:100546.

PMID: 39221179 PMC: 11364133. DOI: 10.1016/j.jvacx.2024.100546.


Assessing the Impact of COVID-19 Vaccination Programs on the Reduction of COVID-19 Cases: A Systematic Literature Review.

Sibanda B, Haryanto B Ann Glob Health. 2024; 90(1):45.

PMID: 39070079 PMC: 11276414. DOI: 10.5334/aogh.4484.


Global trends in COVID-19.

Zhou C, Qin X, Yan L, Jiang Y, Yu X Infect Med (Beijing). 2023; 1(1):31-39.

PMID: 38074976 PMC: 8895648. DOI: 10.1016/j.imj.2021.08.001.


Incidence and risk factors related to SARS-CoV-2 infection, reinfection, and seroconversion: Analysis of a healthcare workers cohort from a university hospital in Colombia.

Nieto M, Caballero N, Remolina C, Moreno S, Vega D, Quintero J IJID Reg. 2023; 9:63-71.

PMID: 37928802 PMC: 10623274. DOI: 10.1016/j.ijregi.2023.09.003.


Efficacy and safety of Lianhua Qingwen capsules combined with standard of care in the treatment of adult patients with mild to moderate COVID-19 (FLOSAN): protocol for a randomized, double-blind, international multicenter clinical trial.

Zhan Y, Chen R, Zheng Q, Li X, Liu Y, Mootsikapun P J Thorac Dis. 2023; 15(5):2859-2872.

PMID: 37324081 PMC: 10267938. DOI: 10.21037/jtd-23-281.


References
1.
Gupta N, Kaur H, Yadav P, Mukhopadhyay L, Sahay R, Kumar A . Clinical Characterization and Genomic Analysis of Samples from COVID-19 Breakthrough Infections during the Second Wave among the Various States of India. Viruses. 2021; 13(9). PMC: 8472862. DOI: 10.3390/v13091782. View

2.
Dodd R, Pickles K, Nickel B, Cvejic E, Ayre J, Batcup C . Concerns and motivations about COVID-19 vaccination. Lancet Infect Dis. 2020; 21(2):161-163. PMC: 7832277. DOI: 10.1016/S1473-3099(20)30926-9. View

3.
Ran L, Chen X, Wang Y, Wu W, Zhang L, Tan X . Risk Factors of Healthcare Workers With Coronavirus Disease 2019: A Retrospective Cohort Study in a Designated Hospital of Wuhan in China. Clin Infect Dis. 2020; 71(16):2218-2221. PMC: 7184482. DOI: 10.1093/cid/ciaa287. View

4.
Hacisuleyman E, Hale C, Saito Y, Blachere N, Bergh M, Conlon E . Vaccine Breakthrough Infections with SARS-CoV-2 Variants. N Engl J Med. 2021; 384(23):2212-2218. PMC: 8117968. DOI: 10.1056/NEJMoa2105000. View

5.
Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz M . BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med. 2021; 384(15):1412-1423. PMC: 7944975. DOI: 10.1056/NEJMoa2101765. View